ClinicalTrials.gg
CompletedNCT05975099Updated Jul 30, 2026Results posted

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

A Phase 1/2 interventional study of mRNA-1975 and mRNA-1982 in Lyme Disease, sponsored by ModernaTX, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
807
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
5th of 33
807 · median 72
Started
2023
with 3 others
Phase 1/2
4 of 54
2 open now
Registered
44th of 54
by date

Among the 54 studies in Lyme Disease with a site in United States, this one is the 5th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 1/2, and was the 44th registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.

03

Conditions studied

  • Lyme Disease

Browse trials for

Keywords

  • mRNA-1975
  • mRNA-1982
  • Vaccine
  • Lyme Disease Vaccine
  • Messenger RNA
  • Moderna
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 18 to 39 kilograms/square meter (inclusive) at the Screening Visit.
  • Participants of nonchildbearing potential may be enrolled in the study.
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy during the study intervention period, and agreement to continue adequate contraception or abstinence through 3 months following last study injection.

Exclusion criteria

Exclusion Criteria:

  • Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician.
  • Received treatment for Lyme disease within the prior 3 months.
  • Had previous vaccination against Lyme disease or participated in the past in any vaccine study for Lyme disease.
  • Had a tick bite within 4 weeks prior to the study injection visit.
  • Dermatologic conditions that could affect local solicited AR assessments (for example, tattoos; psoriasis patches affecting skin over the deltoid areas).
  • Received systemic for >14 days in total within 180 days prior to the Screening Visit (for , ≥10 milligrams/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study.
  • History of myocarditis, pericarditis, or myopericarditis regardless of the timing of past medical history.
  • History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine or intervention that includes one or more of the same components contained in the study injection.
  • Has received systemic immunoglobulins, long-acting biological therapies that affect immune responses (for example, infliximab) or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
807 participants (actual)

Study arms

  • Experimental
    mRNA-1975: Dose 1

    Participants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169.

    Biological: mRNA-1975

  • Experimental
    mRNA-1975: Dose 2

    Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169.

    Biological: mRNA-1975

  • Experimental
    mRNA-1975: Dose 3

    Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169.

    Biological: mRNA-1975

  • Experimental
    mRNA-1975: Dose 4

    Participants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169.

    Biological: mRNA-1975

  • Experimental
    mRNA-1982: Dose 1

    Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169.

    Biological: mRNA-1982

  • Experimental
    mRNA-1982: Dose 2

    Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169.

    Biological: mRNA-1982

  • Experimental
    mRNA-1982: Dose 3

    Participants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169.

    Biological: mRNA-1982

  • Placebo comparator
    Placebo

    Participants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169.

    Biological: Placebo

Interventions

  • BiologicalmRNA-1975

    Dispersion delivered IM

    Also known as: SR1-7

  • BiologicalmRNA-1982

    Dispersion delivered IM

    Also known as: SR1

  • BiologicalPlacebo

    Solution delivered IM

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

    Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 7 days after Day 1 injection

  2. Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection

    Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 7 days after Day 57 injection

  3. Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection

    Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 7 days after Day 169 injection

  4. Number of Participants With Unsolicited AEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 28 days post any injection

  5. Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Study Discontinuation

    A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 up to Month 18

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein (Anti-OspA) Binding Immunoglobulin (IgG) Antibodies for Serotype (SR-1) Antigen Measured by Enzyme-Linked Immunosorbent Assay (ELISA)

    Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values reported greater than upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 41.4 nanograms (ng)/milliliter (mL) and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% confidence interval (CI) for GM value was calculated based on the t-distribution of the log-transformed values , then back transformed to the original scale for presentation.

    Time frame: Days 1, 29, 85 and 197

  2. GMC of Anti-OspA Binding IgG Antibodies for SR-2 Antigen Measured by ELISA

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 1, 29, 85, and 197

  3. GMC of Anti-OspA Binding IgG Antibodies for SR-3 Antigen Measured by ELISA

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 1, 29, 85 and 197

  4. GMC of Anti-OspA Binding IgG Antibodies for SR-4 Antigen Measured by ELISA

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 1, 29, 85 and 197

  5. GMC of Anti-OspA Binding IgG Antibodies for SR-5 Antigen Measured by ELISA

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 1, 29, 85 and 197

  6. GMC of Anti-OspA Binding IgG Antibodies for SR-6 Antigen Measured by ELISA

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 1, 29, 85 and 197

  7. GMC of Anti-OspA Binding IgG Antibodies for SR-7 Antigen Measured by ELISA

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 1, 29, 85 and 197

  8. Geometric Mean Fold Rise (GMFR) of Anti-OspA Binding IgG Antibody Concentration for SR-1 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 41.4 ng/mL and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.

    Time frame: Days 29, 85 and 197

  9. GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-2 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 29, 85 and 197

  10. GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-3 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 29, 85 and 197

  11. GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-4 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 29, 85 and 197

  12. GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-5 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 29, 85 and 197

  13. GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-6 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 29, 85 and 197

  14. GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-7 Antigen

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

    Time frame: Days 29, 85 and 197

Other outcomes

  1. Number of Deaths Related to Study Drug

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Day 1 up to Month 18

07

Results

Posted Jul 30, 2026

Participant flow

Participant flow — Overall Study
MilestonemRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Started1001019910299100104102
Received first injection1001019910299100104101
Received second injection9798979994979996
Received third injection9395909493939295
Full analysis set1001019910299100104101
Safety analysis set1001019910298100105101
Per-protocol set999999999699102100
Completed9484938691889390
Not completed6176168121112
Withdrew: Withdrawal by subject39164425
Withdrew: Protocol violation01000100
Withdrew: Physician decision00101011
Withdrew: Lost to follow-up36393685
Withdrew: Death01010101
Withdrew: Adverse event00100000

Outcome measures

SecondaryGeometric Mean Concentration (GMC) of Anti-Outer Surface Protein (Anti-OspA) Binding Immunoglobulin (IgG) Antibodies for Serotype (SR-1) Antigen Measured by Enzyme-Linked Immunosorbent Assay (ELISA)

Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values reported greater than upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 41.4 nanograms (ng)/milliliter (mL) and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% confidence interval (CI) for GM value was calculated based on the t-distribution of the log-transformed values , then back transformed to the original scale for presentation.

Time frame:
Days 1, 29, 85 and 197
Reported as:
Geometric mean · ng/mL
Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein (Anti-OspA) Binding Immunoglobulin (IgG) Antibodies for Serotype (SR-1) Antigen Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Day 120.9 (20.5 to 21.2)23.2 (20.6 to 26.1)21.1 (20.5 to 21.7)22.8 (20.6 to 25.3)22.0 (20.8 to 23.2)21.2 (20.5 to 21.8)21.6 (20.7 to 22.6)21.6 (20.6 to 22.6)
Day 29132.6 (103.5 to 169.9)210.3 (155.8 to 283.7)337.7 (262.1 to 435.1)341.2 (261.1 to 445.7)143.2 (110.8 to 185.1)173.1 (130.3 to 230.0)286.6 (226.8 to 362.1)23.2 (21.2 to 25.3)
Day 857677.6 (6050.4 to 9742.4)12511.1 (9778.6 to 16007.2)18298.5 (15411.6 to 21726.2)18793.1 (14816.9 to 23836.3)10351.3 (8109.8 to 13212.4)12207.4 (10039.2 to 14843.8)14372.3 (11741.2 to 17593.1)23.0 (20.0 to 26.4)
Day 19718115.3 (15351.1 to 21377.2)21687.1 (17300.1 to 27186.5)33872.8 (28346.7 to 40476.1)38030.2 (31456.3 to 45977.9)21896.2 (17741.4 to 27023.9)27292.0 (22845.8 to 32603.5)27325.6 (22667.0 to 32941.7)24.1 (20.8 to 27.9)
SecondaryGMC of Anti-OspA Binding IgG Antibodies for SR-2 Antigen Measured by ELISA

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 1, 29, 85, and 197
Reported as:
Geometric mean · ng/mL
GMC of Anti-OspA Binding IgG Antibodies for SR-2 Antigen Measured by ELISA
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 116.5 (15.3 to 17.7)17.5 (15.4 to 19.8)17.1 (15.4 to 19.0)17.0 (15.3 to 18.9)18.0 (15.4 to 21.2)
Day 29462.4 (361.2 to 591.9)517.0 (390.2 to 684.9)963.1 (750.9 to 1235.4)1051.5 (812.8 to 1360.2)17.5 (15.1 to 20.1)
Day 8511868.7 (9422.5 to 14949.9)15853.4 (12610.0 to 19931.0)25840.4 (22010.1 to 30337.3)24519.3 (19478.4 to 30864.6)20.8 (15.2 to 28.4)
Day 19719183.3 (16351.5 to 22505.6)21827.7 (17422.6 to 27346.6)36464.7 (31067.1 to 42800.0)38402.4 (32552.4 to 45303.7)21.5 (15.5 to 29.9)
SecondaryGMC of Anti-OspA Binding IgG Antibodies for SR-3 Antigen Measured by ELISA

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 1, 29, 85 and 197
Reported as:
Geometric mean · ng/mL
GMC of Anti-OspA Binding IgG Antibodies for SR-3 Antigen Measured by ELISA
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 110.0 (8.2 to 12.1)9.4 (7.9 to 11.2)8.6 (7.8 to 9.5)9.3 (8.0 to 10.8)10.4 (8.6 to 12.5)
Day 29281.2 (220.1 to 359.4)265.1 (198.6 to 354.0)451.0 (351.9 to 577.9)499.7 (380.1 to 657.0)9.7 (8.1 to 11.5)
Day 8518879.1 (14955.0 to 23833.0)24744.5 (19231.0 to 31838.6)39496.9 (33493.5 to 46576.4)38397.6 (30110.4 to 48965.7)12.2 (8.4 to 17.7)
Day 19730597.1 (26195.4 to 35738.5)34358.4 (27397.3 to 43088.2)53775.7 (45890.0 to 63016.5)59961.2 (51353.0 to 70012.3)10.5 (7.9 to 13.9)
SecondaryGMC of Anti-OspA Binding IgG Antibodies for SR-4 Antigen Measured by ELISA

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 1, 29, 85 and 197
Reported as:
Geometric mean · ng/mL
GMC of Anti-OspA Binding IgG Antibodies for SR-4 Antigen Measured by ELISA
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 117.5 (16.4 to 18.8)18.4 (16.5 to 20.5)17.5 (16.4 to 18.8)18.9 (16.9 to 21.1)17.4 (16.1 to 18.9)
Day 29278.3 (216.7 to 357.4)311.2 (233.9 to 414.0)461.7 (367.1 to 580.8)673.4 (512.3 to 885.1)16.8 (15.8 to 17.7)
Day 857657.5 (6041.3 to 9706.0)10956.1 (8618.8 to 13927.4)16893.9 (14300.6 to 19957.5)17014.8 (13540.2 to 21381.0)19.1 (14.7 to 24.8)
Day 19716321.2 (13797.4 to 19306.7)18558.6 (14731.0 to 23380.8)30140.4 (25139.1 to 36136.6)33650.8 (28045.2 to 40376.9)21.0 (15.7 to 28.1)
SecondaryGMC of Anti-OspA Binding IgG Antibodies for SR-5 Antigen Measured by ELISA

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 1, 29, 85 and 197
Reported as:
Geometric mean · ng/mL
GMC of Anti-OspA Binding IgG Antibodies for SR-5 Antigen Measured by ELISA
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 123.1 (22.6 to 23.7)24.8 (22.5 to 27.4)23.2 (22.6 to 23.7)24.1 (22.2 to 26.2)23.5 (22.4 to 24.7)
Day 29227.8 (181.1 to 286.7)312.8 (237.5 to 411.9)429.2 (342.0 to 538.7)574.3 (447.4 to 737.3)23.5 (22.4 to 24.6)
Day 8512397.8 (9776.0 to 15722.8)18278.8 (14417.0 to 23175.1)28935.8 (24549.3 to 34106.2)29379.4 (23500.4 to 36729.0)26.5 (20.2 to 34.9)
Day 19725936.7 (22160.8 to 30355.9)30441.9 (24264.0 to 38192.7)48316.4 (40666.4 to 57405.4)55926.3 (47330.2 to 66083.6)28.8 (21.3 to 38.8)
SecondaryGMC of Anti-OspA Binding IgG Antibodies for SR-6 Antigen Measured by ELISA

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 1, 29, 85 and 197
Reported as:
Geometric mean · ng/mL
GMC of Anti-OspA Binding IgG Antibodies for SR-6 Antigen Measured by ELISA
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 115.7 (12.9 to 19.0)17.8 (14.2 to 22.5)17.4 (14.0 to 21.7)16.5 (13.3 to 20.6)16.1 (12.4 to 20.8)
Day 29908.6 (686.7 to 1202.2)966.1 (707.5 to 1319.2)1455.3 (1098.3 to 1928.3)2053.0 (1519.8 to 2773.3)17.4 (12.8 to 23.7)
Day 8510562.2 (8398.7 to 13283.0)15196.8 (12110.6 to 19069.5)24822.5 (20955.4 to 29403.1)24350.5 (19698.1 to 30101.7)19.1 (13.2 to 27.6)
Day 19721974.2 (18498.7 to 26102.8)24469.9 (19561.2 to 30610.5)40282.3 (33744.1 to 48087.4)45703.0 (38542.2 to 54194.3)20.5 (13.8 to 30.5)
SecondaryGMC of Anti-OspA Binding IgG Antibodies for SR-7 Antigen Measured by ELISA

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 1, 29, 85 and 197
Reported as:
Geometric mean · ng/mL
GMC of Anti-OspA Binding IgG Antibodies for SR-7 Antigen Measured by ELISA
ng/mLmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 19.5 (7.8 to 11.4)9.4 (7.8 to 11.3)8.9 (7.7 to 10.3)9.3 (7.8 to 11.0)9.9 (8.0 to 12.3)
Day 29360.8 (281.2 to 462.8)314.7 (226.3 to 437.6)567.4 (444.9 to 723.7)730.4 (533.6 to 999.7)9.3 (7.6 to 11.3)
Day 8515651.7 (12231.7 to 20028.0)18865.4 (14538.3 to 24480.3)32934.0 (27492.3 to 39452.9)28756.5 (22583.1 to 36617.5)11.4 (7.8 to 16.6)
Day 19727210.2 (23148.9 to 31984.0)26425.1 (21070.6 to 33140.4)44179.6 (37498.2 to 52051.3)47777.3 (40846.7 to 55883.8)11.0 (7.9 to 15.4)
SecondaryGeometric Mean Fold Rise (GMFR) of Anti-OspA Binding IgG Antibody Concentration for SR-1 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 41.4 ng/mL and ULOQ was 428000 ng/mL for manual assay; LLOQ was 47.6 ng/mL and 583000 ng/mL for automated assay for SR-1 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise (GMFR) of Anti-OspA Binding IgG Antibody Concentration for SR-1 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Day 296.36 (4.96 to 8.15)9.07 (6.97 to 11.81)16.00 (12.45 to 20.56)15.13 (11.87 to 19.28)6.52 (5.09 to 8.35)8.18 (6.18 to 10.83)13.24 (10.45 to 16.77)1.07 (0.99 to 1.16)
Day 85367.86 (289.59 to 467.29)543.18 (424.67 to 694.76)866.31 (728.39 to 1030.33)822.95 (651.97 to 1038.75)470.15 (366.95 to 602.37)581.89 (480.79 to 704.25)662.04 (540.01 to 811.66)1.06 (0.93 to 1.22)
Day 197867.49 (733.47 to 1026.00)938.35 (744.25 to 1183.07)1601.46 (1338.41 to 1916.20)1658.31 (1352.59 to 2033.15)993.15 (794.82 to 1240.96)1300.55 (1088.80 to 1553.50)1253.29 (1036.49 to 1515.44)1.11 (0.96 to 1.26)
SecondaryGMFR of Anti-OspA Binding IgG Antibody Concentration for SR-2 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 30 ng/mL and ULOQ was 214000 ng/mL for manual assay; LLOQ was 66.6 ng/mL and 215000 ng/mL for automated assay for SR-2 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-2 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 2928.03 (22.24 to 35.34)29.49 (22.81 to 38.12)56.25 (44.00 to 71.91)61.84 (47.73 to 80.11)0.97 (0.93 to 1.01)
Day 85718.13 (566.61 to 910.17)902.85 (704.35 to 1157.29)1500.72 (1221.09 to 1844.39)1438.92 (1128.33 to 1835.01)1.15 (0.86 to 1.53)
Day 1971165.32 (984.17 to 1379.80)1236.85 (958.68 to 1595.74)2188.32 (1824.82 to 2624.23)2316.91 (1920.38 to 2795.31)1.19 (0.89 to 1.59)
SecondaryGMFR of Anti-OspA Binding IgG Antibody Concentration for SR-3 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 14.5 ng/mL and ULOQ was 299000 ng/mL for manual assay; LLOQ was 62.5 ng/mL and 296000 ng/mL for automated assay for SR-3 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-3 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 2927.98 (21.92 to 35.70)28.19 (21.73 to 36.57)52.58 (40.16 to 68.84)53.48 (40.99 to 69.76)0.93 (0.86 to 1.01)
Day 851871.56 (1397.22 to 2506.93)2677.78 (2008.72 to 3569.68)4651.11 (3749.37 to 5769.72)4106.89 (3104.97 to 5432.10)1.18 (0.83 to 1.68)
Day 1973249.93 (2735.98 to 3860.42)3689.50 (2820.14 to 4826.86)6328.99 (5160.22 to 7762.48)6487.62 (5164.85 to 8149.16)1.02 (0.77 to 1.36)
SecondaryGMFR of Anti-OspA Binding IgG Antibody Concentration for SR-4 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 32.6 ng/mL and ULOQ was 292000 ng/mL for manual assay; LLOQ was 59.7 ng/mL and 264000 ng/mL for automated assay for SR-4 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-4 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 2915.84 (12.51 to 20.05)16.90 (13.17 to 21.67)26.32 (20.83 to 33.25)36.26 (27.78 to 47.32)0.96 (0.91 to 1.01)
Day 85435.52 (341.99 to 554.63)600.04 (470.06 to 765.97)960.06 (795.84 to 1158.16)901.26 (709.46 to 1144.93)1.09 (0.84 to 1.42)
Day 197923.60 (773.02 to 1103.50)1012.74 (796.67 to 1287.41)1704.02 (1391.81 to 2086.25)1784.54 (1452.04 to 2193.18)1.20 (0.90 to 1.61)
SecondaryGMFR of Anti-OspA Binding IgG Antibody Concentration for SR-5 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 45.5 ng/mL and ULOQ was 298000 ng/mL for manual assay; LLOQ was 84.2 ng/mL and 319000 ng/mL for automated assay for SR-5 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-5 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 299.84 (7.86 to 12.32)12.58 (9.76 to 16.22)18.53 (14.72 to 23.33)23.79 (18.92 to 29.91)1.00 (0.96 to 1.05)
Day 85535.26 (422.24 to 678.54)734.72 (574.47 to 939.67)1248.40 (1051.92 to 1481.58)1221.90 (977.12 to 1528.01)1.13 (0.86 to 1.48)
Day 1971118.45 (957.19 to 1306.88)1220.14 (964.85 to 1542.97)2081.93 (1742.35 to 2487.70)2313.13 (1937.15 to 2762.07)1.22 (0.90 to 1.65)
SecondaryGMFR of Anti-OspA Binding IgG Antibody Concentration for SR-6 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 18.1 ng/mL and ULOQ was 203000 ng/mL for manual assay; LLOQ was 68.7 ng/mL and 248000 ng/mL for automated assay for SR-6 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-6 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 2957.36 (44.30 to 74.28)54.45 (40.29 to 73.59)83.55 (61.40 to 113.68)126.77 (92.88 to 173.02)1.08 (0.88 to 1.34)
Day 85687.70 (530.80 to 890.99)858.93 (628.91 to 1173.07)1448.42 (1066.27 to 1967.54)1459.96 (1098.19 to 1940.90)1.20 (0.97 to 1.47)
Day 1971422.17 (1110.28 to 1821.67)1353.77 (980.02 to 1870.04)2444.57 (1849.48 to 3231.14)2811.21 (2119.73 to 3728.26)1.29 (0.94 to 1.76)
SecondaryGMFR of Anti-OspA Binding IgG Antibody Concentration for SR-7 Antigen

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values reported greater than ULOQ were replaced by the ULOQ. LLOQ was 13 ng/mL and ULOQ was 197000 ng/mL for manual assay; LLOQ was 78.9 ng/mL and 174000 ng/mL for automated assay for SR-7 IgG antibody. 95% CI for GMFR value was calculated based on the t-distribution of the difference in the log-transformed values, then back transformed to the original scale for presentation. Since mRNA-1982 was designed to elicit antibodies against SR-1 antigen only, the data for this outcome measure has been reported for mRNA-1975 and placebo arms only.

Time frame:
Days 29, 85 and 197
Reported as:
Geometric mean · ratio
GMFR of Anti-OspA Binding IgG Antibody Concentration for SR-7 Antigen
ratiomRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4Placebo
Day 2937.83 (29.46 to 48.57)33.46 (24.91 to 44.95)63.76 (48.29 to 84.18)79.96 (58.39 to 109.51)0.93 (0.88 to 1.00)
Day 851634.53 (1211.14 to 2205.93)2059.80 (1545.71 to 2744.87)3764.69 (2894.54 to 4896.43)3085.38 (2305.20 to 4129.62)1.17 (0.82 to 1.65)
Day 1972989.02 (2414.14 to 3700.80)2882.41 (2191.50 to 3791.14)5113.85 (4044.21 to 6466.39)5235.80 (4102.95 to 6681.44)1.13 (0.84 to 1.51)
PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 7 days after Day 1 injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
ParticipantsmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection7080829164778633
PrimaryNumber of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 7 days after Day 57 injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection
ParticipantsmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection7980909670828833
PrimaryNumber of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 7 days after Day 169 injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection
ParticipantsmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection8187819276828826
PrimaryNumber of Participants With Unsolicited AEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 28 days post any injection
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Number of Participants With Unsolicited AEs3838424729383637
PrimaryNumber of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Study Discontinuation

A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 up to Month 18
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Study Discontinuation
ParticipantsmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
MAAEs3938364242404639
AESIs01401222
SAEs44646347
AEs Leading to Study Discontinuation01110001
Other pre-specifiedNumber of Deaths Related to Study Drug

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Day 1 up to Month 18
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug
ParticipantsmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Deaths01010101
Deaths related to study drug00000000

Adverse events

Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation were collected from Day 1 up to Month 18. Other (non-serious) adverse events were collected from the time of injection through 28 days after each injection, unless they met the criteria for SAEs, AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
mRNA-1975 Dose Level 10/100 (0%)4/100 (4%)12/100 (12%)
mRNA-1975 Dose Level 21/101 (1%)4/101 (4%)16/101 (15.8%)
mRNA-1975 Dose Level 30/99 (0%)6/99 (6.1%)6/99 (6.1%)
mRNA-1975 Dose Level 41/102 (1%)4/102 (3.9%)13/102 (12.7%)
mRNA-1982 Dose Level 10/99 (0%)6/98 (6.1%)15/98 (15.3%)
mRNA-1982 Dose Level 21/100 (1%)3/100 (3%)14/100 (14%)
mRNA-1982 Dose Level 30/104 (0%)4/105 (3.8%)9/105 (8.6%)
Placebo1/102 (1%)7/101 (6.9%)12/101 (11.9%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Urinary tract infectionInfections and infestations0/1000/1012/990/1020/980/1000/1050/101
AppendicitisInfections and infestations0/1000/1010/990/1021/980/1000/1050/101
COVID-19Infections and infestations0/1000/1010/990/1021/980/1000/1050/101
Rhinovirus infectionInfections and infestations0/1000/1010/990/1021/980/1000/1050/101
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1000/1010/990/1021/980/1000/1050/101
Cardiac failure acuteCardiac disorders0/1000/1010/990/1021/980/1000/1050/101
Subclavian steal syndromeVascular disorders0/1000/1010/990/1021/980/1000/1050/101
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1000/1010/990/1021/980/1000/1050/101
Renal impairmentRenal and urinary disorders0/1000/1010/990/1021/980/1000/1050/101
PyelonephritisInfections and infestations0/1000/1011/990/1020/980/1000/1050/101
Most frequent other events
Most frequent other events
EventmRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3Placebo
Upper respiratory tract infectionInfections and infestations7/1008/1013/996/1028/988/1006/1055/101
COVID-19Infections and infestations5/1008/1012/997/1026/985/1002/1056/101
RashSkin and subcutaneous tissue disorders1/1002/1011/991/1025/983/1001/1051/101

Baseline characteristics

The Full Analysis Set included all randomly assigned participants who received the study injection.

Age, Continuous
Age, Continuous(years)mRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3PlaceboTotal
Mean48.5 ± 13.7250.5 ± 13.7650.4 ± 14.6649.6 ± 12.8151.1 ± 13.9549.8 ± 15.0548.9 ± 14.7751.2 ± 12.9350.0 ± 13.95
Sex: Female, Male
Sex: Female, Male(Participants)mRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3PlaceboTotal
Female4253575653505458423
Male5848424646505043383
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3PlaceboTotal
Hispanic or Latino611466913863
Not Hispanic or Latino9186919590909093726
Unknown or Not Reported3441311017
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)mRNA-1975 Dose Level 1mRNA-1975 Dose Level 2mRNA-1975 Dose Level 3mRNA-1975 Dose Level 4mRNA-1982 Dose Level 1mRNA-1982 Dose Level 2mRNA-1982 Dose Level 3PlaceboTotal
White7874768477797379620
Black1521201317132218139
Asian5313215424
American Indian or Alaska Native020000103
Native Hawaiian or Other Pacific Islander000001001
Other000100001
Multiple1111151011
Not reported101021207
08

Study locations

20 sites
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Encore Research Group-Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites
    Lake Mary, Florida 32746, United States
  • Clinical Research Atlanta, headlands LLC
    Stockbridge, Georgia 30281, United States
  • Johnson County Clin-Trials, Inc. (JCCT)
    Lenexa, Kansas 66219, United States
  • Centennial Medical Group
    Columbia, Maryland 21045, United States
  • Advanced Primary and Geriatric Care
    Rockville, Maryland 20850, United States
  • DM Clinical Research - Brookline
    Brookline, Massachusetts 02445, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Meridian Clinical Research - Omaha
    Omaha, Nebraska 68134, United States
  • ActivMed Research LLC
    Newington, New Hampshire 03801, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Hatboro Medical Associates/CCT Research
    Hatboro, Pennsylvania 19040, United States
  • Velocity Clinical Research Providence
    Providence, Rhode Island 02886, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
09

References and documents

Publications

  • Finn MB, Willsey G, Piazza CL, Clendenen L, Shrestha M, You SS, Ma L, Dhingra Y, Laciak AR, Uggowitzer KA, Obiero JM, Freeman-Gallant G, Natarajan H, Green S, Pirayesh E, Lai YT, Himansu S, Carfi A, Hu LT, Mantis N, Plante O, Dold C. Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice. NPJ Vaccines. 2026 May 5. doi: 10.1038/s41541-026-01451-7. Online ahead of print. PubMed 42086599 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in May 2025, 22 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 3, 2023
StartActual
Jul 26, 2023
Primary completionActual
May 30, 2025
CompletionActual
May 30, 2025
Results first posted
Jul 30, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05975099
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Aug 3, 2023
Start date
Jul 26, 2023
Primary completion
May 30, 2025
Completion
May 30, 2025
Results posted
Jul 30, 2026
Last update
Jul 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion